Physician profile
Benjamin J Osborne
NPI 1750310504
$746,539.89
in general payments reported to CMS, 2019-2025
21 companies · $103K in 2025
The $103K reported for 2025 was more than what 98% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $89K · 2020: $81K · 2021: $55K · 2022: $89K · 2023: $179K · 2024: $150K · 2025: $103K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $231K · Consulting Fee: $85K · Honoraria: $65K · Travel and Lodging: $36K · Food and Beverage: $16K · Education: $121 · Gift: $78.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $230,935.50 |
| Consulting Fee | $84,582.03 |
| Honoraria | $64,850.00 |
| Travel and Lodging | $35,798.53 |
| Food and Beverage | $16,411.27 |
| Education | $120.71 |
| Gift | $78.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $308,361.10 | 2019-2025 | Ultomiris, Soliris |
| Biogen, INC. | $129,974.89 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Amgen INC. | $123,470.28 | 2024-2025 | Uplizna, Tepezza |
| Horizon Therapeutics Plc | $99,842.56 | 2021-2023 | Uplizna, Tepezza |
| Genentech USA, INC. | $42,321.59 | 2019-2025 | Enspryng, Ocrevus, Ocrevus Zunovo |
| Celgene Corporation | $11,911.97 | 2020-2025 | Zeposia |
| E.R. Squibb & Sons, L.L.C. | $10,218.41 | 2021-2022 | |
| Ucb, INC. | $7,733.56 | 2022-2025 | Rystiggo, Zilbrysq |
| Genzyme Corporation | $5,588.28 | 2019-2025 | |
| Tg Therapeutics, INC. | $2,763.08 | 2023-2025 | Briumvi |
| Emd Serono, INC. | $1,816.86 | 2019-2025 | |
| Catalyst Pharmaceuticals, INC. | $1,200.00 | 2025 | |
| Genentech, INC. | $698.39 | 2022-2025 | Ocrevus, Enspryng |
| Novartis Pharmaceuticals Corporation | $262.80 | 2022-2024 | |
| Abbvie INC. | $150.16 | 2022-2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $116.20 | 2023 | |
| Sanofi-Aventis U.S. LLC | $90.99 | 2019 | |
| F. Hoffmann-La Roche Ag | $18.77 | 2023 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Osborne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.